Silence Therapeutics: Merck Deal Caps Upside at $20 per ADS
Silence Therapeutics is set to be acquired by Merck KGaA in an all-cash deal valued at $1.3 billion, offering $20 per American depositary share (ADS)—a 130% premium. The offer remains subject to shareholder and UK regulatory approval.
The acquisition follows positive Phase 2 results for Silence Therapeutics’ siRNA candidate divesiran. In the SANRECO study, 88% of participants with phlebotomy-dependent polycythemia vera responded to treatment. An analyst has downgraded Silence Therapeutics from Buy to Hold, arguing the offer price limits further upside while approval is pending. If the deal falls through, the company may face funding challenges for Phase 3 trials and could need to raise capital, potentially diluting shareholders.
Neutral
This is a biotechnology acquisition, not a cryptocurrency market event. The Merck deal and its approval conditions have no direct effect on crypto asset fundamentals, trading flows or market stability, so the expected crypto-market impact is neutral. In the short term, crypto traders may see no meaningful change in prices or indicators such as volume and volatility. Longer term, the transaction could contribute marginally to broader risk sentiment, but there is no clear mechanism for a deal of this kind to drive crypto markets. Unlike major rate, regulatory or institutional crypto announcements, this news is unlikely to prompt a comparable market reaction.